| Bioactivity | SYNTi is a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein Interaction. SYNTi exhibits an IC50 value of 400 nM and ligand efficiency (LE) value of 0.24. SYNTi can be used for breast cancer research[1]. |
| Invitro | SYNTi (1-100 μM)显著影响MDA-MB-231细胞的迁移速度和欧氏距离[1]。SYNTi 在浓度高达 100 μM时，在野生型 MDA-MB-231 乳腺癌细胞和具有 syntenin-KO 的 MDA-MB-231 细胞中没有毒性[1]。 |
| Name | SYNTi |
| Formula | C28H24BrFN2O5 |
| Molar Mass | 567.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hoffer L, et al. Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein-Protein Interaction: A Semi-Automated "Hit Identification-to-Optimization" Approach. J Med Chem. 2023 Apr 13;66(7):4633-4658. |